Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Viral Vector Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The global market for viral vector manufacturing has witnessed remarkable growth over the past decade. In 2024, the market recorded revenue of US$ 800 million, and it is projected to reach a valuation of US$ 3000 million by the end of 2031. These insights were shared by Fairfield Market Research in their latest report on the viral vector manufacturing market.

The report reveals that adeno-associated viral vectors, securing a market value of US$ 209.6 million in 2021, have played a pivotal role in driving market growth. Viral vectors, essential tools for effective gene transfer, have become a cornerstone in gene and cell therapy, contributing significantly to the modification of specific tissues or cell types to induce therapeutic effects.

Viral vectors, both in-vitro and in-vivo, have proven instrumental in activating cellular immunity and humoral responses, making them a preferred choice for vaccines against various malignancies and infectious disorders. Additionally, the escalating demand for gene therapy due to the rising number of patients with chronic and hereditary diseases further propels the growth of viral vector manufacturing.

The World Health Organization's revelation that ten in every thousand individuals encounter some form of genetic disease underscores the urgent need for gene therapy, thereby driving the demand for viral vectors.

Key Drivers of Viral Vector Manufacturing Growth

One of the primary drivers of the escalating demand for viral vector manufacturing is its extensive use in T-cell engineering for cancer treatment. Viral vectors, particularly lentiviral vectors, have played a crucial role in the development of gene-modified cell-based therapeutics, especially T-cell therapies, which have shown clinical efficacy and safety in patients with B-cell malignancies.

Furthermore, the approval of the first genetically engineered cellular therapy by the FDA, utilizing lentiviral vectors, has paved the way for advancements in CAR T-cell therapy. This evolution is expected to contribute significantly to the viral vector manufacturing market's growth.

The report also highlights the substantial role of viral vectors in vaccine development, including the production of COVID-19 vaccines. The unique characteristics of viral vectors, such as low pathogenicity, genetic safety, and efficacy in antigen expression, position them as ideal candidates for vaccine delivery systems.

Challenges and Barriers

Despite the promising growth, viral vector manufacturing faces challenges that could impact its development. Critical factors include the selection of a suitable production system, the development of quality assays, and the optimization of downstream processing. Additionally, the high cost of gene therapies poses a potential barrier to the market's expansion over the forecast period.

Country-wise Insights

The United States remains a prominent player in the viral vector manufacturing market, accounting for 92.1% share in the North American region in 2023. The presence of key manufacturers such as ThermoFisher Scientific Inc., Waisman Biomanufacturing, and others contributes to the country's dominance in the market.

The United Kingdom, with a 22.9% share of the European market in 2023, is witnessing rapid growth due to increased research activities related to cancer treatment. Lentiviral vectors are extensively studied for T-cell engineering, contributing to the market's expansion.

China emerges as a significant market, holding the largest share of 48.2% in the East Asia market in 2023. The growth is attributed to the expansion of manufacturing units, collaborative strategic planning, and the construction of new facilities like the 34,000 square meter GMP manufacturing facility by GenScript ProBio.

Competitive Analysis

Major viral vector producers are adopting strategic alliances, product launches, and acquisitions to enhance their market presence. For instance, SIRION Biotech partnered with the Centre for Genomic Regulation to create novel adeno-associated virus vectors for type 1 and type 2 diabetic gene therapy. ThermoFisher Scientific Inc. opened a cutting-edge manufacturing facility in August 2022, further strengthening its position in the viral vector manufacturing market.

In conclusion, the global viral vector manufacturing market is poised for substantial growth, driven by advancements in gene and cell therapy, vaccine development, and increased research activities. Despite facing challenges, strategic collaborations and expansions are expected to propel the market towards new heights, with the United States, the United Kingdom, and China leading the way.

Key Companies Profiled
• Thermo Fisher Scientific Inc
• Charles River (Cobra Biologics)
• Novasep
• uniQure N.V.
• Waisman Biomanufacturing
• Creative Biogene
• GenScript Biotech Corporation
• Novartis AG
• Merck KGaA.
• Takara Bio Inc.
• FUJIFILM Diosynth Biotechnologies
• Lonza
• Danaher Corp. (Aldevron)
• Sirion-Biotech GmbH
• AGC Biologics

Key Segments of Manufacturing of Viral Vector Industry Research

by Virus Type:
• Lentiviral Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Retrovirus

by Expression System:
• Transient
• Stable

by Application:
• Gene Therapy
• Vaccines
• Cancer Therapy
• Others

by End User:
• Biotechnology Companies
• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic and Research Institutes

by Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.